15 Nov EULAR 2026: Falling IgG After Treatment May Help Track Response in Lyme Arthritis
Health Notice: This interview discusses a conference abstract from a retrospective, single-center study, and the findings are considered hypothesis-generating. It is for educational purposes only and is not medical advice. Anyone with joint swelling after a tick bite, or questions about Lyme disease testing or treatment, should speak with their own doctor.

Dr. Med. Anna Mihailova
MedicalResearch.com Interview with:
Dr. med. Anna Mihailova
Orto Clinic
Riga, Latvia
EULAR 2026 Abstract AB0041:
Clinical and Serological Markers and Treatment Response in Lyme Arthritis (Puce S, Mihailova A)
MedicalResearch.com: What is the background for this study?
Response: Lyme arthritis is a late manifestation of Lyme borreliosis, caused by Borrelia burgdorferi sensu lato, and is endemic in Europe, including Latvia. It remains a diagnostic challenge, particularly in endemic European regions such as Latvia, where several Borrelia species circulate.
Diagnosis relies on two-tier serological testing, and patients with Lyme arthritis typically have strong Borrelia-specific IgG responses. In endemic regions, however, background seroprevalence is high and IgG antibodies often persist long after successful treatment. This makes a single positive result difficult to interpret and limits the use of serology to monitor treatment response. We wanted to describe the clinical presentation, the antibody profile, and changes in IgG levels after treatment in a real-world European cohort.
MedicalResearch.com: What are the main findings?
Response: We retrospectively reviewed records of 67 patients diagnosed with Lyme arthritis at our outpatient clinic between January 2018 and December 2023 (42 women, 25 men; age 19–84 years, median 51.5 years). All had elevated Borrelia-specific IgG and ultrasound-confirmed inflammatory joint changes, supporting the clinical diagnosis of arthritis. Patients with other inflammatory or degenerative arthropathies were excluded.
Clinical presentation: Monoarthritis was present in 33 patients, oligoarthritis in 28 and polyarthritis in 6. The knee was the most commonly affected joint, involved in 64% of monoarthritis and 45% of oligoarthritis cases.
Antibody profile: Median baseline IgG was 185.05 AU/mL (IQR 107.4–240). On immunoblot (31 patients), the most frequent IgG bands were VlsE (B. garinii, 84%), p41 (81%), VlsE (B. afzelii, 61%), VlsE (B. burgdorferi sensu stricto, 61%), p39 (61%) and p83 (55%). This reflects strong responses to late Borrelia antigens and the multi-species exposure typical of Europe.
Post-treatment dynamics: IgG levels fell significantly after treatment, to a median of 117.3 AU/mL (IQR 64.45–201) at about 3 months and 68.86 AU/mL (IQR 40.6–173.05) at about 6 months (p < 0.05). Among 20 patients with serial measurements and clinical follow-up, the 13 who improved clinically showed a significant decline in IgG titers (p < 0.05). The 7 nonresponders showed no statistically significant change (p > 0.05).
MedicalResearch.com: What should readers take away from your report?
Response: IgG seropositivity usually persists after treatment, so a positive test alone should not be read as treatment failure or active infection. A falling IgG level in the months after therapy may support clinical improvement, while stable levels may suggest nonresponse. Antibody dynamics, rather than absolute serostatus, may therefore offer supportive information when judging treatment response.
They may also help distinguish persistent seropositivity from ongoing disease activity or, especially, reinfection, particularly in endemic regions. Serology should always be interpreted alongside clinical findings and joint imaging to support clinical judgment.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Prospective, multicenter studies with larger cohorts and standardized sampling time points (for example, baseline, 3, 6 and 12 months) to confirm that IgG decline predicts clinical response.
Standardization of quantitative IgG assays and agreed definitions of a clinically meaningful decline, so that results can be compared across laboratories.
Analysis of how individual immunoblot bands, especially species-specific VlsE antigens, change over time, and whether particular profiles predict persistent or antibiotic-refractory arthritis.
Correlation of antibody kinetics with ultrasound findings, synovial fluid testing such as Borrelia PCR, and patient-reported outcomes.
Closer study of non-responders, including their response to further antibiotic or anti-inflammatory treatment, to clarify the roles of persistent infection versus post-infectious inflammation.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: This was a retrospective single-center study, and only 20 of 67 patients had serial antibody measurements with clinical follow-up, so the findings should be considered hypothesis-generating. We hope they encourage clinicians in endemic areas to follow antibody trends rather than rely on a single result.
Disclosures: None declared.
For more interviews on Lyme disease, see Lyme disease research on MedicalResearch.com.
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 15, 2026 by Marie Benz MD FAAD